Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives
By Ben Glickman Pulmatrix will close a study of a potential treatment for a fungal lung infection as it prioritizes limiting cash burn and pursuing strategic...
Ted Raad Ben Glickman Allergic Bronchopulmonary Aspergillosis Chief Executive Ted Raad Article Normal Biotechnology Services
Source: marketwatch.com